Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek A Persons

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2010
Lentiviral vector gene therapy: effective and safe?Derek A Persons
Hematology. American Society of Hematology. Education Program|December 17, 2009
Hematopoietic stem cell gene transfer for the treatment of hemoglobin disordersDerek A Persons
Nature|September 17, 2010
Gene therapy: Targeting β-thalassaemiaDerek A Persons
Current Opinion in Molecular Therapeutics|November 7, 2003
Update on gene therapy for hemoglobin disordersDerek A Persons
Annals of the New York Academy of Sciences|August 18, 2010
The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patientsDerek A Persons
Current Opinion in Drug Discovery & Development|February 20, 2008
Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell diseaseJeffrey Lebensburger, Derek A Persons
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2011
Solving the problem of γ-retroviral vectors containing long terminal repeatsDerek A Persons, Christopher Baum
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 22, 2012
Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cellsMd Nasimuzzaman, Derek A Persons
Current Opinion in Molecular Therapeutics|November 19, 2002
In vivo selection to improve gene therapy of hematopoietic disordersDerek A Persons, Arthur W Nienhuis
Seminars in Hematology|October 28, 2004
Gene therapy for the hemoglobin disordersDerek A Persons, John F Tisdale
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2010
Lentiviral vector gene therapy: effective and safe?Derek A Persons
Hematology. American Society of Hematology. Education Program|December 17, 2009
Hematopoietic stem cell gene transfer for the treatment of hemoglobin disordersDerek A Persons
Nature|September 17, 2010
Gene therapy: Targeting β-thalassaemiaDerek A Persons
Current Opinion in Molecular Therapeutics|November 7, 2003
Update on gene therapy for hemoglobin disordersDerek A Persons
Annals of the New York Academy of Sciences|August 18, 2010
The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patientsDerek A Persons
Current Opinion in Drug Discovery & Development|February 20, 2008
Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell diseaseJeffrey Lebensburger, Derek A Persons
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2011
Solving the problem of γ-retroviral vectors containing long terminal repeatsDerek A Persons, Christopher Baum
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 22, 2012
Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cellsMd Nasimuzzaman, Derek A Persons
Current Opinion in Molecular Therapeutics|November 19, 2002
In vivo selection to improve gene therapy of hematopoietic disordersDerek A Persons, Arthur W Nienhuis
Seminars in Hematology|October 28, 2004
Gene therapy for the hemoglobin disordersDerek A Persons, John F Tisdale
Pageof 6